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Background: Darunavir has been proven efﬁcacious for antiretroviral-experienced HIV-1-
infected  patients in randomized trials. However, effectiveness of darunavir-based salvage
therapy  is understudied in routine care in Brazil.
Methods: Retrospective cohort study of HIV-1-infected patients from three public refer-
ral  centers in Belo Horizonte, who received a darunavir-based therapy between 2008 and
2010,  after virologic failure. Primary endpoint was the proportion of patients with viral
load  < 50 copies/mL at week 48. Change in CD4 cell count was also evaluated. Outcome
measures  were analyzed on an intent-to-treat basis applied to observational studies. Sensi-
tivity analysis was conducted to evaluate the impact of missing data at week 48. Predictors
of  virologic failure were examined using rare-event, ﬁnite sample, bias-corrected logistic
regression.
Results:  Among 108 patients, the median age was 44.2 years, and 72.2% were male. They
had  long-standing HIV-1 infection (median 11.6 years) and advanced disease (76.9% had an
AIDS-deﬁning event). All patients had previously received protease inhibitors and nucleo-
side  reverse transcriptase inhibitors, 75% nonnucleoside reverse transcriptase inhibitors,
and  4.6% enfuvirtide. The median length of protease inhibitor use was 8.9 years, and 90.8%
of  patients had prior exposure to unboosted protease inhibitor. Genotypic resistance pro-
ﬁle  showed a median of three primary protease inhibitor mutations and 10.2% had three or
more darunavir resistance-associated mutations. Virologic success at week 48 was achieved7–86%) of patients and mean CD4 cell count increase from baseline wasby 78.7% (95% CI = 69.131.5  cells/L (95% CI = 103.4–159.6). In multiple logistic regression analysis, higher baseline
viral  load (RR = 1.04 per 10,000 copies/mL increase; 95% CI = 1.01–1.09) and higher number
of  darunavir resistance-associated mutations (RR = 1.23 per each; 95% CI = 0.95–1.48) were
independently  associated with virologic failure.
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Conclusion: Virologic suppression is a realistic endpoint for most treatment-experienced
patients  who begin a darunavir-based therapy outside the controlled conditions of a ran-
domized trial, at routine care settings.
13 EIntroduction
The improved potency and tolerability of antiretroviral (ARV)
drugs  and the accumulated knowledge about their ideal com-
bination  enabled a higher proportion of long-term virologic
suppression in randomized clinical trials of initial ARV ther-
apy  (ART) in HIV-1-infected patients.1–5 Cohort studies also
showed  an increased virologic response with initial ART,
evidencing the applicability of clinical trials results to the clin-
ical  practice.6,7 Additionally, studies that analyzed clinical out-
comes  of initial ART found no signiﬁcant divergence between
efﬁcacy  in clinical trials and effectiveness in routine care.8,9
There is cumulative evidence from randomized trials
that  treatment of ARV-experienced patients with third-line
drugs  is efﬁcacious.10–14 However, salvage therapy remains
understudied in routine clinical care, especially in low- and
middle-income countries.15–19 Therefore, it is important to
ascertain  clinical outcomes of third-line drugs outside the
controlled  conditions of a randomized trial and in the Brazil-
ian  context. In this study, we assessed virologic, immunologic,
and  clinical outcomes of ARV-experienced patients who ini-
tiated  darunavir (DRV)-based salvage therapy in routine care
settings.  We  also analyzed risk factors associated with viro-
logic  failure.
Materials  and  methods
We  conducted a retrospective cohort study to evaluate viro-
logic  and immunologic response and risk factors for virologic
failure  in patients from three public referral centers (one ter-
tiary  center and two secondary centers) for HIV treatment in
Belo Horizonte, Brazil, failing ART (viral load ≥ 50 copies/mL)
and  that started a DRV-based regimen between 2008 and 2010.
Adult  patients (≥18 years) on regular follow-up and with a HIV-
1  drug-resistant virus (at least 1 primary protease inhibitor
mutation) and/or a treatment history of unboosted protease
inhibitor  in a failing regimen were  eligible. Patients without
a  genotyping test performed in the 18 months prior to DRV-
based  therapy and those who received etravirine, tipranavir,
maraviroc or vicriviroc concurrently with DRV were  excluded,
as  these drugs were  not then available through the Brazilian
Public  Health Care System.
Patient clinical charts were reviewed to gather data about
demographic characteristics, baseline and nadir CD4 cell
count,  baseline and highest viral load, ART history, cumu-
lative  genotype, and optimized background therapy (OBT).
The  cumulative genotype was  obtained by summing up all
the  resistance mutations detected in the latest and histori-
cal  genotyping resistance tests.20,21 ARV resistance mutations
© 20were  deﬁned according to the December 2009 International
AIDS Society-USA (IAS-USA) list.22 The genotypic sensitivity
was  based on the Brazilian Algorithm for Interpretation ofHIV-1  Genotype – version 10 (www.aids.gov.br), that assigned
three levels of drug resistance: susceptible (S), intermediate-
level resistance (I) or high-level resistance (R). To assess the
number  of active drugs in the DRV-based therapy, a genotypic
sensitivity score was calculated by assigning a score for each
drug,  based on the level of viral resistance (i.e., of 1 to S, 0.5
to  I and 0 to R) and then adding up the scores. Raltegravir and
enfuvirtide  were  considered fully active drugs (S) except for
patients  with previous use in a failing regimen.17
Primary endpoint was the proportion of patients with viral
load  < 50 copies/mL at week 48 (±4 weeks). Secondary end-
points  were changes from baseline in CD4 cell counts, and
the  proportion of patients who experienced an AIDS-deﬁning
event or death. Analysis was conducted on an intent-to-treat
basis applied to observational studies.23 The following were
considered treatment failures if they occurred before week 52:
patient death, DRV interruption for any cause, or any change
in  the OBT resulting in higher antiviral activity. For virologic
endpoint, these patients were considered as virologic failures
and  for the immunologic endpoint, changes from baseline
CD4  cell counts were  considered as being zero. For all other
situations  with missing viral load and/or CD4 cell count at
week  48 (±4), two strategies for data analysis were  adopted.
In  strategy 1, the ﬁrst available information after week 52
was  carried backward and, when the latter was  unavailable,
the  last observation before week 44 was  carried forward. As
for  strategy 2, last observation before week 44 was  carried
forward  and any available information after week 52 was
ignored.
In  the descriptive analysis, values of qualitative variables
were  expressed in terms of absolute and relative frequencies,
and  values of numerical variables as median, 25th and 75th
percentiles. The Kolmogorov–Smirnov test and visual inspec-
tion  of histograms were used to test the normal distribution of
quantitative  data. Differences in the distribution of numerical
variables  between baseline and week 48 (±4) were  analyzed by
the Wilcoxon test.
In  univariate analysis of unmatched groups, categorical
data were compared using analysis of contingency tables and
chi-square  test or Fisher exact test, as appropriate; numerical
variables were  compared using the Mann–Whitney U-test.
Multiple  regression analysis of factors associated with viro-
logic  failure was conducted using logistic regression models
with  backward manual elimination of variables. Candidate
variables were  those associated with virologic failure with
a  p-value ≤ 0.3 in the univariate analysis, as well as those
with  high clinical relevance, irrespective of their statistical
signiﬁcance. Variables with a p-value ≤ 0.1 and those with
signiﬁcant effect modiﬁcation on clinically relevant variables
were  kept in the ﬁnal models. The method proposed by King
  lsevier  Editora  Ltda.  Este é um artigo Open Access sob a licença de CC BY-NC-NDand  Zeng and implemented in the ReLogit© macro for Stata
was  used to adjust regression coefﬁcients for the rare event,
ﬁnite  sample bias.24–26 The commands setx and relogitq,





















































Table 1 – Demographic and baseline characteristics of
patients.
Characteristic Value
Median age, years (Q1–Q3) 44.2 (40–49.3)
Male sex, n (%) 78 (72.2)
Median time since diagnosis of HIV infection,
years (Q1–Q3)
11.6  (9.6–13.4)
Median time since last genotype test, months
(Q1–Q3)
6.4 (4.2–9.8)
CDC group C, n (%) 83  (76.9)
Median nadir CD4 cell count, cells/L (Q1–Q3) 78 (33–157)
Median baseline CD4 cell count, cells/L (Q1–Q3) 200 (91–351)
Median highest viral load, log10 copies/mL (Q1–Q3) 5.2 (4.6–5.5)
Median baseline viral load, log10 copies/mL (Q1–Q3) 4.2 (3.7–4.7)
Previous antiretroviral therapy
PI,  NNRTI and NRTI use, n (%) 81 (75)
Median number of regimens, n (Q1–Q3) 5 (4–6)
Median length of use, years (Q1–Q3) 10.9 (9–12.3)
Median number of failing antiretroviral regimens,
n (Q1–Q3)
3  (2–4)
Median length of PI exposure, years (Q1–Q3) 8.9 (6.8–10.8)
NNRTI use, n (%) 81 (75)
Median length of NNRTI exposure, years (Q1–Q3) 1.7 (0.1–3.5)
Mono or dual antiretroviral therapy, n (%) 49 (45.4)
Unboosted-PI use, n (%) 98  (90.8)
Median length of unboosted-PI exposure, years (Q1–Q3) 3.8  (2.1–5.6)
Baseline cumulative genotype mutations
Median number of TAMs, n (Q1–Q3) 3 (2–4)
Median number of NNRTI RAMs, n (Q1–Q3) 2 (0.5–2)
Median number of primary PI mutations, n (Q1–Q3) 3 (2–4)
≥3 darunavir RAMs, n (%) 11 (10.2)
Data for darunavir-based salvage therapy
Raltegravir use, n (%) 67 (62)
Enfuvirtide use, n (%) 39 (36.1)
Number of antiretrovirals, n (%)
3  8 (7.4)
4 65 (60.2)
5 or 6 35 (32.4)
Overall genotypic sensitivity score, n (%)
≤2 24 (22.3)
>2 and ≤3 67 (62)
>3 17 (15.7)
Q1–Q3, 25th and 75th percentiles; CDC, Center for Disease Con-
trol and Prevention; PI, protease inhibitor; NRTI, nucleoside reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase
inhibitor;  RAMs, resistance-associated mutations; TAM, thymidine-b r a z j i n f e c t d
vailable in the same macro, were  used to estimate the effect
izes  of variables in terms of relative risks instead of odds
atios.
Statistical analyses were  performed with Stata for Win-
ows  (version 11.2, StataCorp, College Station, TX).
This  study was  conducted in accordance with Resolution
96/96 of the Brazilian National Research Ethics Commission
CONEP) and had the approval by the Research Ethics Commit-
ees  of each participating center.
esults
verall, 108 patients met  inclusion criteria and were  eligi-
le  for analysis. Demographic and baseline characteristics
re described in Table 1. Most were  male adults from Belo
orizonte  metropolitan area (86.1%). They had long-standing
IV-1 infection and advanced disease, as conﬁrmed by the
igh  proportion of past AIDS-deﬁning events and low nadir
D4  cell count. Patients also had an extensive ART history
ith  a signiﬁcant exposure to unboosted protease inhibitor
90.8%);  still, only 10.2% had three or more  DRV resistance-
ssociated mutations (RAMs). Among those who received
 DRV-based therapy, raltegravir association was  common
nd  most patients had more  than two fully active drugs
77.7%).
At  week 48, virologic success (viral load < 50 copies/mL) was
chieved  by 85 patients (78.7%; 95% CI = 69.7–86%) according
o  strategy 1 for handling missing data, and by 87 patients
80.6%; 95% CI = 71.8–87.5%) according to strategy 2. In strat-
gy  1 analysis, 56.5% had a viral load available after week
2  carried backward and 8.3% had a viral load available
efore week 44 carried forward; 66.7% of the latter were  from
eek  36 or after. In strategy 2, 63% had a viral load avail-
ble  before week 44 carried forward and 79.4% were from
eek  36 or after. Mean CD4 cell count increase from baseline
as  131.5 cells/L (95% CI = 103.4–159.6; p < 0.001) considering
trategy 1 and 107.7 cells/L (95% CI = 83.5–131.9; p < 0.001) for
trategy  2.
Seven  patients (6.5%) were  diagnosed with eight AIDS-
eﬁning events before week 52: Candida esophagitis (n = 2),
neumocystis  pneumonia (n = 2), and one case each of recur-
ent  pneumonia, Cryptococcus meningoencephalitis, extra-
ulmonary  tuberculosis, and non-Hodgkin B-cell lymphoma.
ne  patient was  diagnosed with visceral leishmaniasis. Up to
eek 52, three patients (2.8%) died. Two of them had previously
een  diagnosed with opportunistic infections (Pneumocys-
is  pneumonia and Cryptococcus meningoencephalitis). One
atient  withdrew DRV before week 52 to avoid drug interac-
ion  with rifampin, prescribed for conﬁrmed extrapulmonary
uberculosis.
In  univariate analysis, considering both strategies for
andling missing data, higher baseline viral load, higher viral
oad  at anytime, lower nadir CD4 cell count, and lower number
f  previous failing ARTs were independently associated with
irologic  failure (Tables 2 and 3). In multiple logistic regression
odels,  irrespective of the strategy for handling missing data,
igher  viral load and higher number of DRV-RAMs were  predic-
ive  of virologic failure. Conversely, use of a higher number of
revious  failing ARTs was  associated with virologic success.associated mutation.
Other variables associated with virologic failure were  longer
exposure  to nonnucleoside reverse transcriptase inhibitors
(NNRTI), longer time since HIV diagnosis, younger age, and
shorter  time since last genotype test, although their signiﬁ-
cance  was  more  sensible to the strategy for handling missing
data  (Table 4).
Twelve  patients had previously used regimens containing
fosamprenavir/r before DRV initiation. Patients with previ-
ous  use of fosamprenavir/r had signiﬁcantly more  DRV-RAMs
(median = 1; p25–p75 = 0–2) than patients with no previous use
(median  = 2; p25–p75 = 1–3) (p = 0.016), although no signiﬁcant
univariate or multivariate association with 48-week virologic
failure  was  observed.
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Table 2 – Comparison of baseline patient characteristics (categorical data), according to virologic failure at week 48 (±4).













n % n % p-Valueb n % n % p-Valueb
Male sex 62 72.9 16 69.6 0.748 63 72.4 15 71.4 0.928
CDC group 0.904c 0.806c
A 5 5.9 1 4.3 5 5.7 1 4.8
B 16 18.8 3 13.0 14 16.1 5 23.8
C 64 75.3 19 82.6 68  78.2 15 71.4
Previous antiretroviral therapy
PI,  NNRTI and NRTI use 64 75.3 17 73.9 0.892 65 74.7 16 76.2 0.888
NNRTI use 64 75.3 17 73.9 0.892 65 74.7 16 76.2 0.888
Mono or dual antiretroviral therapy 42 49.4 7 30.4 0.105 42 48.3 7 33.3 0.217
Unboosted-PI use 79 92.9 19 82.6 0.215c 81 93.1 17 82.0 0.101c
Number of DRV RAMs 0.658c 0.644c
0 or 1 60 70.6 14 60.9 61 70.1 13 61.9
2 17 20.0 6 26.1 17 19.5 6 28.6
3 or more 8 9.4 3 13.0 9 10.3 2 9.5
Data for DRV-based salvage therapy
Overall  genotypic sensitivity score 0.286 0.535c
≤2 17 20.0 7 30.4 18 20.7 6 28.6
>2 and ≤3 56 65.9 11 47.8 56 64.4 11 52.4
>3 12 14.1 5 21.7 13 14.9 4 19.0
Number of antiretrovirals 0.384 0.761
3 6 7.1 2 8.7 7 8.0 1 4.8
4 54 63.5 11 47.8 53 60.9 12 57.1
5 or 6 25 29.4 10 43.5 27 31.0 8 38.1
Enfuvirtide use 31 36.5 8 34.8 0.881 31 35.6 8 38.1 0.833
Raltegravir use 54 63.5 13 56.5 0.539 54 62.1 13 61.9 0.989
CDC, Centers for Disease Control; DRV, darunavir; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PI, protease inhibitor; RAMs, resistance-associated mutations.
a Strategies for handling missing data (see “Materials and methods” section for deﬁnitions).
b By chi-square test, except when indicated otherwise.
c By Fisher’s exact test.
Discussion
In this study of HIV-1-infected patients who initiated a DRV-
based  salvage therapy, virologic success at week 48 was
achieved by about 80% of patients and the mean CD4 cell count
increase  from baseline exceeded 100 cells/L. Higher base-
line  viral load (RR = 1.04 per 10,000 copies/mL increase; 95%
CI  = 1.01–1.09) and higher number of DRV-RAMs (RR = 1.23 per
each;  95% CI = 0.95–1.48) were independently associated with
48-week  virologic failure.
Patients in our cohort had more  advanced disease (CDC
group  C 76.9%) than patients who initiated a DRV-based sal-
vage  therapy in the POWER randomized trials (36%)11 and in
a  previous Brazilian prospective cohort from São Paulo (65%)
published  by Vidal et al.18 The proportion of patients with
three  or more  primary protease inhibitor mutations was  also
higher  that in the POWER trials (60.2% vs. 54%).11 Still, the pro-
portion  of patients with three or more  DRV-RAMs (10.2%) was
lower  than in the POWER trials (22%)11 and higher than in the
São  Paulo cohort (7.6%).18 Another retrospective cohort fromSão  Paulo by Schontag et al.19 reported a 15.3% prevalence of
two  or more  DRV-RAMs, which is also signiﬁcantly lower than
in  our cohort (31.5%). As for treatment history, the current
cohort  had less NNRTI exposure (75%), considering that in the
POWER  trials and São Paulo cohort all patients had received
NNRTI.11,18 Despite the lower proportion of previous NNRTI
use,  our patients were highly exposed to unboosted protease
inhibitors (90.8%) and mono or dual ART (45.4%), factors shown
to  be associated with virologic failure in previous studies.27,28
The proportion of patients with virologic success at week
48  in our study (about 80%) was  higher than in the POWER tri-
als  (61%)11 but slightly lower than in the two Brazilian cohorts
(82.6%  and 84.7%).18,19 This may  be mainly related to dif-
ferences in the proportion of DRV-RAMs reported between
studies. Differences in the composition of the OBT are also
a  likely explanation. All patients in the cohort of Vidal et al.18
received an OBT with at least one drug of a new class (enfuvir-
tide,  raltegravir or maraviroc), while this proportion was  only
82.4%  in our cohort. In agreement with the high rate of viro-
logic  success, immunologic response was also signiﬁcant. The
estimated  mean CD4 cell count increase from baseline varied
b r a z j i n f e c t d i s . 2 0 1 4;1  8(1):1–7  5
Table 3 – Comparison of baseline patient characteristics (numerical data), according to virologic failure at week 48 (±4).














Age, years 43.8 (40.7–48.8) 44.6 (37.1–52.1) 0.607 45.2 (40.9–49.9) 43.7 (35.5–47.6) 0.088
Time since diagnosis of HIV infection, years 11.7  (9.6–13.6) 11.0 (9.2–12.5) 0.275 11.5 (9.4–13.3) 11.7 (9.6–14.3) 0.558
Nadir CD4 cell count, cells/L 80  (34–173) 76 (13–138) 0.252 85 (36–173) 39 (13–107) 0.040
Highest viral load, copies/mL 5.0 (4.6–5.5) 5.3 (4.9–5.6) 0.104 5.0 (4.4–5.5) 5.3 (5.2–5.6) 0.006
Time since last genotype test, months 6.8 (4.4–9.8) 5.3 (3.7–9.3) 0.234 6.9 (4.5–9.9) 4.6 (3.4–5.8) 0.010
Baseline viral load, copies/mL 4.1 (3.7–4.6) 4.7 (3.9–5.1) 0.047 4.1 (3.7–4.6) 4.7 (4.2–5.1) 0.003
Baseline CD4 cell count, cells/L 202 (119–329) 175 (47–362) 0.483 223 (115–356) 141 (85–329) 0.227
Previous antiretroviral therapy
Overall  length of antiretroviral use,
years
11.0 (9.1–12.5) 10.6 (8.9–11.8) 0.257 10.9 (9.0–12.3) 10.3 (9.2–11.8) 0.786
Number of antiretroviral regimens 5 (4–6) 4 (3–5) 0.118 5 (4–6) 4 (3–5) 0.424
Number of failing antiretroviral
regimens
3  (2–4) 2 (1–4) 0.018 3 (2–4) 2 (2–4) 0.076
Length of PI exposure, years 9.0 (6.8–10.9) 7.8 (7.0–10.4) 0.313 8.9 (6.8–10.8) 8.9 (7.3–10.6) 0.920
Length of unboosted-PI exposure,
years
3.8  (2.1–5.6) 3.9 (1.9–6.2) 0.979 4.0 (2.1–5.7) 3.2 (1.5–4.8) 0.400
Length of NNRTI exposure, years 1.5  (0.1–3.2) 2.3 (0.0–5.6) 0.154 1.6 (0.0–3.2) 2.4 (0.2–4.7) 0.228
Baseline cumulative genotype mutations
Number  of TAMs 3 (3–4) 3 (1–4) 0.203 3 (2–4) 3 (3–4) 0.794
Number of NNRTI RAMs 2 (1–2) 2 (0–2) 0.810 2 (0–2) 1 (1–2) 0.650
Number of primary PI mutations 3 (2–4) 3 (2–4) 0.865 3 (2–4) 3 (2–4) 0.814
Number of DRV RAMs 1 (0–2) 1 (0–2) 0.307 1 (0–2) 1 (0–2) 0.546
DRV, darunavir; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAMs, resistance-associated mutations; TAM,
thymidine-associated mutation.
a Strategies for handling missing data (see “Materials and methods” section for deﬁnitions).
b All values are median (25th and 75th percentiles).
c By Mann–Whitney’s test.
Table 4 – Multiple logistic regression analysis of factors associated with virologic failure at week 48 (±4).
Variable Strategy 1a Strategy 2a
RR (95% CI) p-Value RR (95% CI) p-Value
Baseline viral load (per 10,000 copies/mL) 1.04 (1.01–1.09) 0.007 1.10 (1.02–1.21) 0.001
Number of darunavir resistance mutations (per each) 1.23 (0.95–1.48) 0.069 1.58 (1.09–2.36) 0.023
Number of previously failing ART (ref: 1 or 2)
3 or 4 0.23 (0.08–0.56) 0.003 0.22 (0.07–0.67) 0.060
5 or more 0.23 (0.07–0.73) 0.006 0.18 (0.02–0.91) 0.037
Length of previous NNRTI exposure (per year) 1.19 (1.05–1.42) 0.010 NA NA
Time since diagnosis of HIV infection (per 10-year period) NA NA 2.91 (1.46–8.35) 0.001
Age (per year) NA NA 0.92 (0.83–0.99) 0.009
Length of previous unboosted PI exposure (per year) NA NA 0.85 (0.64–1.04) 0.151
Number of TAMs (ref: 0–2)
3  or more NA NA 1.99 (0.89–6.19) 0.091
Number of primary PI mutations (ref: 0–3)
4 or more NA NA 0.38 (0.09–1.37) 0.135
Time since last genotype test (per month) 0.94 (0.83–1.02) 0.144 0.80 (0.58–0.98) 0.032
Intercept – 0.131 – 0.231
RR, relative risk; CI, conﬁdence interval; ART, antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; NA, not applicable;
PI, protease inhibitor; TAM, thymidine-associated mutation.
a Strategies for handling missing data (see “Materials and methods” section for deﬁnitions).
d i s .
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between 107.7 cells/L and 131.5 cells/L, and was  similar to
the  POWER trials (102 cells/L)11 and the study by Vidal et al.
(118  cells/L).18
In multiple logistic regression analysis, higher baseline
viral  load was  signiﬁcantly predictive of virologic failure as in
the subgroup analyses of TORO, BENCHMRK, DUET,10,14,29 and
the  previous Brazilian studies.18,19 In addition, higher num-
ber  of DRV-RAMs were associated with virologic failure. This
is  in line with the POWER trials results, in which three or
more  DRV-RAMs were  associated with a lower proportion of
virologic  success.11 In turn, the association found between
longer duration of NNRTI exposure and virologic failure may
be  in part explained by the higher proportion of two-drug class
resistance  in patients exposed to a NNRTI-containing regi-
men  when compared with those receiving a boosted protease
inhibitor-based therapy.4
Unexpectedly, in the ﬁnal logistic regression models, viro-
logic  failure was  less likely in patients with three or more
previous failing ARTs. This counterintuitive ﬁnding may
reﬂect  a prescription bias favoring patients with more  previ-
ous  failing ARTs. Indeed, in patients with two or less failing
ARTs,  the proportion of raltegravir and enfuvirtide use in the
OBT  was, respectively, 42.1% and 21.1%. In patients with three
or  four previous failing ARTs, these proportions were 71.2%
and  40.4%, respectively. Evidence suggests that the improved
antiviral  activity of third-line drugs may  overcome the poor
treatment  history of patients.11,13,14 This was  illustrated in a
study  that showed lower rates of virologic failure over time in
patients with triple-class failure, reducing from 80% in 2000
to  48% in 2007.27 Another reason for the improved virologic
response among highly ART-experienced patients may  be a
higher level of adherence to ART as compared to patients with
less  previous ART exposure. A further explanation for this
association could be a survivor bias.
Older age at baseline was  also associated with higher viro-
logic  success. Higher adherence to ART in older HIV-1-infected
patients, previously reported by some authors, may  account
for  this ﬁnding.30–32
Due to the retrospective nature of our study, ART adher-
ence  could not be effectively measured. Accordingly, previous
argumentations regarding ART adherence levels remain spec-
ulative.
The  main limitation of this study was  the presence of
missing  data on viral load and CD4 cell counts at week 48
(±4).  This is a common problem in clinical research, even
in  well-designed randomized controlled trials, but is more
frequent  in observational studies with prolonged follow-up.33
In studies where efforts to avoid missing data failed, four
different  types of adjustment methods for analysis may  be
used:  complete-case analysis, single imputation methods,
estimating-equation methods, and methods based on a sta-
tistical  model.33,34 However, there is no consensus about the
best  method for handling missing data in clinical studies.34,35
This is because all these methods are based on assumptions
that, although scientiﬁcally plausible, are always empirically
unveriﬁable.34 On the other hand, in these situations there is
consensus  that sensitivity analyses should be conducted to
assess the robustness of the ﬁndings to plausible alternative
assumptions about the missing data mechanism.34,36 In our
study,  we conducted sensitivity analysis by comparing two
1 2 0 1 4;1  8(1):1–7
strategies for handling missing data (see “Materials and
methods” section). It is worth noting that the rate of virologic
success  and the mean change in CD4 cell count were  not
highly  sensitive to how missing values were  treated. Regarding
risk  factors for virologic failure listed in Table 4, although they
were  less robust to the missing values assumptions, ﬁndings
from  both models are more  complementary than conﬂicting.
In  conclusion, virologic suppression is a realistic goal
for  most treatment-experienced HIV-1-infected patients who
begin a DRV-based therapy even in routine care settings in
Brazil.
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